

Extra references [Posted as supplied by author]

w1. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled prospective study of the effects of Atorvastatin on proteinuria and progression of kidney disease. *Am J Kidney Dis* 2003;41:565-70.

w2. Gheith OA, Sobh M, Mohamed K, El-Husseini F, Gazarin SS, Ahmed HA, et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. *Nephron* 2002;91:612-19.

w3. Hommel E, Andersen P, Gall M, Nielsen F, Jensen B, Rossing P, et al. Plasma lipoproteins and renal function during Simvastatin treatment in diabetic nephropathy. *Diabetologia* 1992;35:447-51.

w4. Lam KS, Cheng I, Janus E, Pang R. Cholesterol lowering therapy may retard the progression of diabetic nephropathy. *Diabetologia* 1995;38:604-09.

w5. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, et al. Effect of Cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. *Nephrol Dial Transplant* 2002;17:798-802.

w6. Nielsen S, Schmitz O, Moller N, Pørksen N, Klausen IC, Alberti KG, et al. Renal function and insulin sensitivity during Simvastatin treatment in type 2 (non-insulin dependent) diabetic patients with microalbuminuria. *Diabetologia* 1993;36:1079-86.

- w7. Rayner BL, Byrne MJ, Van Zyl Smit R.A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with Simvastatin and diet, versus diet alone. *Clin Nephrol* 1996;46:219-24
- w8. Holmberg B, Brannstrom M, Bucht B, Crougneau V, Dimeny E, Ekspong A, et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. *Scand J Urol Nephrol* 2005;39:503-10.
- w9. Thomas ME, Harris KP, Ramaswamy C. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. *Kidney Int*1993;44:1124-29
- w10. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. *Circulation* 2004;110:1557-63
- w11. Tonolo G, Ciccarese M, Brizzi P. Reduction of albumin excretion rate in Normotensive patients during longterm Simvastatin treatment. *Diabetes Care*1997;20:1891-95
- w12. Imai Y, Suzuki H, Saito T, Tsuji I, Abe K, Saruta T. The effects of Pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. *Clin Exp Hypertens* 1999;21:1345-55
- w13. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-1) Study: Biochemical efficacy

and safety of Simvastatin and safety of low dose aspirin in chronic kidney disease. *Am J Kidney Dis* 2005;45:473-84

w14. Van Dijk M, Kamper A, Van Veen S, Souverijn J, Blaum G. Effect of Simvastatin on renal function in autosomal dominant polycystic kidney disease. *Nephrol Dial Transplant* 2001;16:2152-57..

w15. Zhang A, Vertrommen J, Gaal V, Leeuw D. Effects of Pravastatin on lipid levels, in vitro oxidability of non-HDL lipoproteins and microalbuminuria in IDDM patients. *Diabetes Res Clin Pract* 1995;29:189-94

w16. Lee TM, Lin MS, Tsai CH, Chang NC. Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT1 receptor blockers. *Kidney Int* 2005; 68: 779–87.

w17. Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: Effect on microvascular outcomes. *J Diabetes Complications* 2001;15:113–19.

w18. Scanferla F, Toffoletto PP, Roncali D, Bazzato G. Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. *Am J Hypertens* 1991;4: 868–74.

w19. Yasuda G, Kuji T, Hasegawa K, Ogawa N, Shimura G, Ando D, et al. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. *Ren Fail* 2004; 26: 411–18.

w20. Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G, et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. *Clin Pharmacol Ther* 2000; 67: 427–31.

w21. Dalla Nora E, Passaro A, Zamboni PF, Calzoni F, Fellin R, Solini A. Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study. *J Endocrinol Invest* 2003;26:73-8

w22. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. *Hypertension* 2002;40:67-73.

w23. Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. *Am J Cardiol* 2005;96:1290-2..

w24. Collins R, Armitage J, Parish S, Sleight P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* 2003;361:2005-16.

w25. Asselbergs FW, Diercks DFH, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al. Effects of Fosinopril and Pravastatin in cardiovascular events in subjects with macroalbuminuria. *Circulation* 2004;110:2809-16.

w26. Lemos PA, Serruys PW, de Feyter P, Mercado NF, Goedhart D, Saia F, et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). *Am J Cardiol* 2005;95:445-51.

w27. Diepeveen SH, Verhoeven GW, Van Der Palen J, Dikkeschei LD, Van Tits LJ, Kolsters G, et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. *J Intern Med* 2005;257:438-45.

w28. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. *Nephrol Dial Transplant* 2002;17(8):1513-7.

w29. Harris KP, Wheeler DC, Chong CC, Atorvastatin in CAPD Study Investigators, Continuous ambulatory peritoneal dialysis. A placebo controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. *Kidney Int* 2002;61(4):1469-74.

w30. Lins RL, Matthys KE, Billiouw JM, Dratwa M, Dupont P, Lameire NH, et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. *Clin Nephrol* 2004;62:287-94.

w31. Walker RJ, Sutherland WH, Walker HL, MaMahon S, Robson RA. Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT study Collaborative Group. *Nephrol Dial Transplant* 1997;12:87-92.

w32. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. *Am J Kidney Dis* 2002;39(2):283-90

w33. Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL, Pieper JA. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. *Pharmacotherapy* 2005 ;25:335-44.

w34. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. *Am J Kidney Dis* 2002;39:1213-7.

w35. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, et al. The effect of pravastatin on acute rejection after kidney transplantation--a pilot study. *Transplantation* 1996;61:1469-74.

w36. Tuncer M, Suleymanlar G, Ersoy FF, Yakupoglu G. Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. *Transplant Proc* 2000;32:622-5.

w37. Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ, Bastani B. The effects of lipid-lowering agents on acute renal allograft rejection. *Transplantation* 2001;72:223-27.

w38. Holdaas H, Jardine AG, Wheeler DC. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. *Kidney Int* 2001;60:1990-97.

w39. Sahu K, Sharma R, Gupta A. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. *Clin Transplant* 2001;15:173-75.

w40. Renders L, Mayer-Kadner I, Koch C. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. *Nephrol Dial Transplant* 2001;16:141-46.

w41. Santos AF, Keitel E, Bittar AE, Neumann J, Fuchs FD, Goldani JC, et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. *Transplant Proc* 2001;33:1194-95.

w42. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. *Lancet* 2003; 361:2024-31.

w43. Lepre F, Rigby R, Hawley C, Saltissi D, Brown A, Walsh Z. A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. *Clin Transplant* 1999;13:520-25.

w44. Arnadottir M, Eriksson LO, Germershausen JI, Thysell H. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients. double-blind, randomized, placebo-controlled study in 40 patients. *Nephron* 1994;68:57-62..

w45. Martinez Hernandez BE, Persaud JW, Varghese Z, Moorhead J. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. *Nephrol Dial Transplant* 1993;8:637-41.

w46. Kosch M, Barenbrock M, Suwelack B, Schaefer RM, Rahn KH, Hausberg M. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. *Am J Kidney Dis* 2003;41:1088-96.

w47. Paczek L, Bill M, Wyzgal J. Influence of hypolipemia treatment on cadaver kidney transplant. *Polskie Archiwum Medycyny Wewnetrznej* 1997;97:144-56.

w48. Cofan F, Zambon D, Laguna JC, Casals E, Ros E, Cofan M, et al. Pravastatin improves low-density lipoprotein oxidation in renal transplantation. *Transplant Proc* 2002;34:389-91.

w49. Castela AM, Grino JM, Andres E, Gilvernet S, Serón D, Castiñeiras MJ et al. HMG CoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation. *Transplant Proc* 1993;25:1043-6.